Systematic analysis of genotype-specific drug responses in cancer

International Journal of Cancer

Volumn 131, Issue 10, 2012, Pages 2456-2464

  Kim, Nayoung ^a   He, Ningning ^a   Kim, Changsik ^a   Zhang, Fan ^b   Lu, Yiling ^b   Yu, Qinghua ^b   Stemke Hale, Katherine ^b   Greshock, Joel ^c   Wooster, Richard ^c   Yoon, Sukjoon ^a   Mills, Gordon B ^b  

^a Sookmyung Women's University   (South Korea)

^b UNIVERSITY OF TEXAS   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

cancer cell line modeling; cancer genotype; drug sensitivity and resistance; network analysis; reverse phase protein assay

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53; PROTEOME; TRANSCRIPTOME;

ARTICLE; CANCER CELL CULTURE; CANCER GENETICS; CANCER RESISTANCE; CELL LINE ENRICHMENT ASSAY; DRUG RESPONSE; GENE CLUSTER; GENE EXPRESSION; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEOMICS; STATISTICAL ANALYSIS; TRANSCRIPTOMICS;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CLUSTER ANALYSIS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENETIC ASSOCIATION STUDIES; GENOMICS; GENOTYPE; HUMANS; MUTATION; NEOPLASMS; PROTEOME; PROTEOMICS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84867070656     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27529     Document Type: Article

References (27)

1. Danesi R, de Braud F, Fogli S, de Pas TM, Di Paolo A, Curigliano G, Del Tacca M,. Pharmacogenetics of anticancer drug sensitivity in non-small cell lung cancer. Pharmacol Rev 2003; 55: 57-103.
2. Cheok MH, Evans WE,. Acute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy. Nat Rev Cancer 2006; 6: 117-29.
3. Marsh S, McLeod HL,. Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet 2006; 15 (Spec No 1): R89-93.
4. Amatschek S, Koenig U, Auer H, Steinlein P, Pacher M, Gruenfelder A, Dekan G, Vogl S, Kubista E, Heider KH, Stratowa C, Schreiber M, et al. Tissue-wide expression profiling using cDNA subtraction and microarrays to identify tumor-specific genes. Cancer Res 2004; 64: 844-56.
5. Dawany NB, Tozeren A,. Asymmetric microarray data produces gene lists highly predictive of research literature on multiple cancer types. BMC Bioinformatics 2010; 11: 483.
6. Di Nicolantonio F, Arena S, Gallicchio M, Zecchin D, Martini M, Flonta SE, Stella GM, Lamba S, Cancelliere C, Russo M, Geuna M, Appendino G, et al. Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proc Natl Acad Sci USA 2008; 105: 20864-9.
7. Shoemaker RH,. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006; 6: 813-23.
8. Wan P, Li Q, Larsen JE, Eklund AC, Parlesak A, Rigina O, Nielsen SJ, Bjorkling F, Jonsdottir SO,. Prediction of drug efficacy for cancer treatment based on comparative analysis of chemosensitivity and gene expression data. Bioorg Med Chem 2012; 20: 167-76.
9. Shivakumar P, Krauthammer M,. Structural similarity assessment for drug sensitivity prediction in cancer. BMC Bioinformatics 2009; 10 (Suppl 9): S17.
10. Tiikkainen P, Poso A, Kallioniemi O,. Comparison of structure fingerprint and molecular interaction field based methods in explaining biological similarity of small molecules in cell-based screens. J Comput Aided Mol Des 2009; 23: 227-39.
11. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci USA 2007; 104: 19936-41.
12. Greshock J, Bachman KE, Degenhardt YY, Jing J, Wen YH, Eastman S, McNeil E, Moy C, Wegrzyn R, Auger K, Hardwicke MA, Wooster R,. Molecular target class is predictive of in vitro response profile. Cancer Res 2010; 70: 3677-86.
13. Settleman J,. Cell culture modeling of genotype-directed sensitivity to selective kinase inhibitors: targeting the anaplastic lymphoma kinase (ALK). Semin Oncol 2009; 36: S36-41.
14. Bamford S, Dawson E, Forbes S, Clements J, Pettett R, Dogan A, Flanagan A, Teague J, Futreal PA, Stratton MR, Wooster R,. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer 2004; 91: 355-8.
15. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, Chary KK, Reimers MA, Scherf U, Kahn A, Dolginow D, Cossman J, Kaldjian EP, et al. Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 2007; 6: 820-32.
16. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, Hennessy BT, Tseng H, Pochanard P, Kim SY, Dunn IF, Schinzel AC, et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16: 21-32.
17. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 2008; 68: 6084-91.
18. Tibes R, Qiu Y, Lu Y, Hennessy B, Andreeff M, Mills GB, Kornblau SM,. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells. Mol Cancer Ther 2006; 5: 2512-21.
19. Hand DJ, Mannila H, Smyth P,. Principles of data mininged. Cambridge, MA: MIT Press, 2001.
20. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T,. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res 2003; 13: 2498-504.
21. Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 358-62.
22. Carson DA, Lois A,. Cancer progression and p53. Lancet 1995; 346: 1009-11.
23. Hainaut P, Hollstein M,. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000; 77: 81-137.
24. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M,. TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 2007; 26: 2157-65.
25. Misawa A, Hosoi H, Arimoto A, Shikata T, Akioka S, Matsumura T, Houghton PJ, Sawada T,. N-Myc induction stimulated by insulin-like growth factor I through mitogen-activated protein kinase signaling pathway in human neuroblastoma cells. Cancer Res 2000; 60: 64-9.
26. Coulter DW, Wilkie MB, Moats-Staats BM,. Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation. Anticancer Res 2009; 29: 1943-9.
27. Huang M, Kamasani U, Prendergast GC,. RhoB facilitates c-Myc turnover by supporting efficient nuclear accumulation of GSK-3. Oncogene 2006; 25: 1281-9.